

**OGILVY  
RENAULT****Facsimile**

Our File: 1770-214US JQ/sw

**Confidentiality Message**

This communication sent by facsimile is confidential, may be privileged and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If the addressee cannot be reached or is unknown to you, please inform us immediately by telephone (613) 230-6072 at our expense and delete this message and all copies. Thank you.

Number of pages including cover letter: 6  
Date: July 30, 2003  
From: Jennifer Quinn  
Telephone: (613) 780-8678  
E-mail: jquinn@ogilvyrenault.com

To	Company	City	Fax
Examiner: Ram SHUKLA Art Unit: 1632	United States Patent Office, Facsimile Center	Alexandria, VA	(703) 746-3103

**URGENT**

In re Application of: KARAPLIS, Andrew C. et al.

Filed: 31 August 2001  
Serial No.: 09/806,110  
Title: USE OF PEX IN THE TREATMENT OF  
METABOLIC BONE DISEASES  
Examiner: SHUKLA, Ram  
Group Art Unit: 1632

Please see Preliminary Amendment attached.

Barristers and Solicitors  
Patent and Trade-Mark Agents

45 O'Connor Street  
Suite 1700  
Ottawa, Ontario  
Canada K1P 1A4

Telephone (613) 230-6072  
Fax (613) 230-6706  
ogilvyrenault.com

Continuing the practices of  
Melghem Demers  
Ogilvy Renault  
Swabey Ogilvy Renault

Montréal • Ottawa • Québec • Toronto • Vancouver • London (England)

Received from &lt;613 230 6706&gt; at 7/30/03 10:35:02 AM [Eastern Daylight Time]

#16/B  
AP  
8-7-03

File No.: 1770-214US JQ/sm/sw

DATE: July 30, 2003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:** KARAPLIS, Andrew C. et al.  
**Filed:** 31 August 2001  
**Serial No.:** 09/806,110  
**Title:** USE OF PEX IN THE TREATMENT OF  
METABOLIC BONE DISEASES  
**Examiner:** SHUKLA, Ram  
**Group Art Unit:** 1632

---

**Mail Stop Non-Fee Amendment**

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
U.S.A.

**PRELIMINARY AMENDMENT**

Sir:

Please amend the above-identified patent application as follows:

A listing of the claims appears on pages 2 to 4 of this paper.

Remarks appear on page 5 of this paper.

**LISTING OF CLAIMS**

This listing of the claims replaces all prior versions and listings of  
claims in the application: